Combination alpha blocker and phosphodiesterase 5 inhibitor versus alpha-blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: A systematic review and meta-analysis

Chen P.-C.Wang C.-C.YU-KANG TU2022-05-102022-05-1020201879-5226https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089661770&doi=10.4103%2fUROS.UROS_59_19&partnerID=40&md5=a4d5fcf5b897511cf6bacff8941e921ahttps://scholars.lib.ntu.edu.tw/handle/123456789/610150[SDGs]SDG3Combination alpha blocker and phosphodiesterase 5 inhibitor versus alpha-blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: A systematic review and meta-analysisreview10.4103/UROS.UROS_59_192-s2.0-85089661770